ImmunityBio Investors Can Take Action Against Securities Violations Following Recent Allegations

Investor Deadline for ImmunityBio, Inc. Class Action

ImmunityBio, Inc., traded as NASDAQ: IBRX, is currently facing a class action lawsuit following significant investor losses. The law firm Robbins Geller Rudman & Dowd LLP has issued an announcement inviting investors who acquired ImmunityBio shares between January 19, 2026, and March 24, 2026, to consider acting as lead plaintiffs in the pending legal proceedings. The deadline to seek this role is May 26, 2026.

The case, which is steeped in allegations of securities law violations, highlights troubling claims about ImmunityBio's promising treatment, Anktiva. According to the case details, ImmunityBio and its Executive Chairman allegedly misrepresented the potential and effectiveness of Anktiva in treating patients with Non-Muscle Invasive Bladder Cancer (NMIBC). The complaint stipulates three primary allegations:

1. Misleading Efficacy Statements: The suit claims that ImmunityBio promoted Anktiva with assertions that it could render all NMIBC patients cancer-free in the long term. However, no conclusive evidence supports this bold claim.

2. False Vaccine Claims: The class action further argues that ImmunityBio's assertion that Anktiva functions as a cancer vaccine is untrue, casting doubt on the integrity of the company’s promotional materials.

3. Overstatements by Company Leadership: The Executive Chairman, Dr. Patrick Soon-Shiong, is accused of significantly exaggerating the drug’s efficacy during the class period.

An additional blow to ImmunityBio occurred on March 24, 2026, following the revelation of a warning letter from the U.S. Food and Drug Administration (FDA) to CEO Richard Adcock. This letter highlighted regulatory violations linked to the promotional messaging for Anktiva, citing concerns about public health due to misleading claims suggesting the drug could cure all types of cancer. The consequence of this revelation was swift; the company's stock plummeted by 21%, a clear indicator of the market's reaction to the potential implications of these allegations.

The Role of Lead Plaintiff in the Lawsuit

Under the Private Securities Litigation Reform Act of 1995, investors who purchased or acquired ImmunityBio securities during the class period can pursue the position of lead plaintiff. This individual not only represents the interests of all class members but works closely with the selected law firm to guide the lawsuit. Interestingly, an investor’s chance to receive a portion of any settlement or recovery is not contingent upon being appointed lead plaintiff; all shareholders have the potential to benefit from the case’s outcome.

About Robbins Geller Rudman & Dowd LLP

Robbins Geller is recognized as one of the foremost law firms in the field of securities fraud and shareholder rights. With a robust track record, they secured over $916 million for investors in 2025 alone, earning them the top spot on the ISS Securities Class Action Services report. Over the past five years, they have recovered a staggering $8.4 billion for their clients, which is unparalleled in the industry, reflecting their dedication to investor rights and legal accountability.

If you have suffered substantial losses due to your investments in ImmunityBio, the opportunity to take part in this class action is crucial. For more information on how to join this action, individuals are encouraged to visit Robbins Geller’s dedicated webpage or contact the attorneys directly at 800-449-4900.

This situation underscores the importance of accountability in the biotech sector, particularly where emerging treatments claim to offer groundbreaking successes in public health. As this case unfolds, it serves as a reminder to investors to remain vigilant and informed regarding the companies they support.